Abstract
Objective. To study the clinical efficacy and safety of epirisone hydrochloride (Stezium) in the treatment of patients with skeletal muscle pain. Material and methods. One hundred forty-two 142 patients with non-specific musculoskeletal pain, mean age 46.2±17.8 years, have been enrolled in the study. The study was conducted according to the registered indication for Stezium — diseases of the musculoskeletal system accompanied by painful muscle spasms. Patients received Stezium 75 mg, extended-release, film-coated tablets, twice a day after meals for 14 days. All patients had undergone clinical examination before the prescription of the drug and on the 15th day using a visual analogue scale (VAS), a verbal analogue scale for pain assessing, a visual analogue scale (EQ-VAS) for the European Quality of Life Questionnaire (EQ-5D-3L), and patient assessment of the treatment effectiveness with Likert scale. Results. Quantitative indicators of pain assessment using analog scales statistically significant decreased (p<0.001) against the background of the treatment with Stezium, which indicates a significant analgesic effect of the therapy. Analysis of patient’s health condition showed an increase in the quality of life (from 60.22±10.45 to 74.11±11.53 points; p<0.001), which confirms the effectiveness of the performed therapy. The patient’s assessment of the overall treatment effect on the Likert scale demonstrated positive trend — 85.21% of patients noted significant clinical effect. Conclusion. The study results demonstrated the clinical efficacy and safety of extended-release film-coated tablets eperisone hydrochloride 75 mg for the treatment of musculoskeletal pain.

This publication has 24 references indexed in Scilit: